FDA Updates

Clinical Trials

Medical Device News

Lonza and ALSA Ventures Collaborate to Provide Development and Manufacturing Services for Biotech Firms

Latest Posts

Abraham Verghese MD Appointed to the Board of Directors of Athos Therapeutics

"Abraham Verghese MD is a highly distinguished physician, humanist, administrator, and adviser," said Allan Pantuck, MD, MS, FACS, Chairman & CMO.

University of Nebraska Medical Center and ANANDA Scientific announce FDA approval of the IND for a Clinical Trial exploring Treatment for Post-Traumatic Stress Disorder

The study will evaluate the effectiveness of Nantheia™ ATL5, an investigational drug-using cannabidiol in ANANDA’s proprietary delivery technology. An investigational new drug (IND) application for the trial has been approved by the FDA.

BRIM Biotechnology & Ora Announce New Partnership

BRIM Biotechnolgy notes the new partnership builds on the success of our previous collaboration for Phase 2 trials and will help to speed the progression of BRM421 through late-stage clinical development toward regulatory filing.

Cytel Designed & Led TOGETHER Trial Wins Society of Clinical Trial’s David Sackett Trial of the Year Award

TOGETHER trial has enrolled over 6000 patients in 22 research sites in Brazil.  It is now expanding to Pakistan and South Africa, Rwanda, DRC, and Vietnam.

Lonza and ALSA Ventures Colloboration: ALSA Ventures, a London based European biotech investment firm, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, announced today a framework collaboration agreement to help ALSA’s portfolio of pre-clinical and early clinical biotechs develop and manufacture biologics and small molecule drug candidates.

The biopharmaceutical industry is experiencing a global shift towards new molecular formats and more complex molecules, including bi- and multispecific antibodies, fusion proteins, and various types of bioconjugates. In addition, small molecules continue to play a vital role in innovative treatments. As these therapies gain complexity in their applications and properties, unique challenges related to their bioavailability and handling arise. Developing and manufacturing these increasingly complex modalities requires sophisticated facility design and expertise, which is often challenging to establish in-house.

The new framework collaboration will support with due diligence into ALSA’s potential investments, which will assist with their investment de-risking. It will also provide a unique opportunity for ALSA Ventures’ portfolio companies to leverage Lonza’s experience in supporting accelerated development and manufacturing projects, global network and regulatory competence. Lonza’s tailored offering includes early de-risking, development and manufacturing, and optimization services for large molecule biologics, bioconjugates and complex proteins, as well as small molecules.

Pnina Weitz, Global Head of Venture Capital Business Development and Relationship Management, Lonza, commented: “Our framework agreement with ALSA Ventures will provide support for ALSA’s portfolio companies during the development and manufacturing of their innovative therapies based on a wide range of biologics and small molecules formats. The collaboration aims to significantly increase the chances for the future success of these therapies by providing early de-risking and development and manufacturing services tailored to each molecule’s unique needs and properties.”

Alek Safarian, CEO of ALSA Ventures, added: “This framework agreement is a vital piece of the support ecosystem ALSA is developing to assist portfolio companies. Lonza’s comprehensive approach to development and manufacturing new treatments across multiple platforms will allow our early-stage portfolio companies to access the best support and expertise available from the earliest stages of development.”

Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 employees (full-time equivalent), we comprise high-performing teams and individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021.

ALSA Ventures is a life science venture capital investor, focused on early-stage novel therapeutics. With a strong operations background in drug development, the team seeks to bring together outstanding entrepreneurs and world class academic researchers to help bring promising new treatments to market. ALSA invests across a wide spectrum of therapeutic areas, targeting high unmet need with impactful outcomes for patients and society at large.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine